ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag intellectual property ecology disease medicine

Flux and Uncertainty in the CRISPR Patent Landscape
Aggie Mika | Oct 1, 2017 | 10 min read
The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.
Week in Review: December 5–9
Tracy Vence | Dec 11, 2016 | 6 min read
Anonymity prevails in PubPeer litigation; USPTO hears CRISPR IP arguments; critical incident reporting for preclinical research; brain waves and Alzheimer’s disease; Breakthrough Prizes
2018 Top 10 Innovations
The Scientist | Dec 1, 2018 | 10+ min read
Biology happens on many levels, from ecosystems to electron transport chains. These tools may help spur discoveries at all of life's scales.
Biotech Faces Evolving Patent System
Douglas Steinberg | Mar 5, 2000 | 8 min read
Like medieval alchemists, modern biologists apply intricate, esoteric protocols to lowly matter, such as bacteria and rodents. Unlike alchemists, biologists successfully transmute these creatures into gold--disease-fighting pharmaceuticals and profits accruing from them. An indispensable ingredient in this dross-to-drug process is patent protection, which preserves monopoly and attracts investment. Unfortunately, the patent system isn't as ideal a catalyst as the chimerical philosopher's stone s
Of Cells and Limits
Anna Azvolinsky | Mar 1, 2015 | 9 min read
Leonard Hayflick has been unafraid to speak his mind, whether it is to upend a well-entrenched dogma or to challenge the federal government. At 86, he’s nowhere near retirement.
Imagining a Cure
Nicholas P. Restifo and Megan Bachinski | Apr 10, 2011 | 5 min read
For cancer patients, close is not good enough.
Imagining a Cure
Nicholas P. Restifo and Megan Bachinski | Apr 1, 2011 | 5 min read
For cancer patients, close is not good enough.
Ethics and war challenge biologists
Eugene Russo(erusso@the-scientist.com) | Mar 24, 2003 | 4 min read
Despite low turnout, ideals and impassioned discussion dominate AIBS meeting.
When Science Has a Potential Payoff
Karen Pallarito(kpallarito@the-scientist.com) | Jan 16, 2005 | 8 min read
In a recent three-hour session at a Chicago hotel room, the University of Wisconsin's technology transfer office hammered out the final details of licensing deal that granted Durham, NC-based Inspire Pharmaceuticals the right to use several patents to develop glau coma treatments.
BioShanghai
Christopher Torrens(ctorrens@the-scientist.com) | Oct 9, 2005 | 8 min read
Think of China, and what comes to mind?

Run a Search

ADVERTISEMENT